Introduction: The clinical trial landscape is no longer confined to the four walls of a research clinic. Decentralized clinical trials (DCTs) – which incorporate remote and virtual elements – have leapt forward, accelerated by technological advances and lessons from the COVID-19 pandemic. Patients might consent at home, receive study medication by courier, report symptoms through smartphone apps, and even have home nursing visits for assessments. ICH E6(R3) explicitly acknowledges these evolving trial models and provides a flexible GCP framework to accommodate them. However, decentralized trials must uphold the same standards for participant protection and data quality. In this blog, we explore how regulators (via E6(R3)) expect sponsors and investigators to manage decentralized trials, and we share practical tips for implementing DCT components successfully.
What Does ICH E6(R3) Say About Decentralized Trials?
While the term “decentralized” itself is relatively new, many of its components are covered in E6(R3). The guideline doesn’t create a separate set of rules for DCTs; instead, it integrates them into existing GCP principles. Key points include:
- Flexibility in Trial Execution: E6(R3) Principle 7 emphasizes proportionate trial conduct and avoiding unnecessary burdens on participants. Decentralized elements align with this by potentially reducing travel and inconvenience for participants. The guideline implies that if remote methods can achieve the same objectives safely, they are allowed. For example, “trial-related procedures may be conducted at locations other than traditional research sites if appropriate oversight is in place.” In practice, this means things like telemedicine consultations, local lab use, or home health visits are all acceptable as long as they are planned and managed properly.
- Clarity on Roles and Responsibilities: A significant concern in DCTs is ensuring who is responsible for what when tasks are spread out. E6(R3) Principle 10 (and Annex 1) stress that trial roles and responsibilities must be clearly defined and documented. If a sponsor hires a home nursing service, that should be outlined (e.g., in the protocol or a separate document) with details on what that nurse will do and how the investigator will remain informed. If a mobile app is used to collect data, specify who monitors that data and how often. Essentially, decentralization is fine, but there should be no ambiguity in oversight. The investigator remains ultimately responsible for trial conduct at their site, and the sponsor remains responsible for overall data quality and safety monitoring – no activity is truly “outsourced” in terms of accountability.
- Combined IRB/Regulatory Review and Patient Involvement: The guideline explicitly supports that regulatory and ethics reviews can be combined or simplified, which many decentralized trials benefit from (for instance, using a central IRB for a trial that spans many geographies). References are made to public (patient) involvement and diversity – DCTs can enhance these by reaching broader populations. Sponsors are encouraged to justify their trial design choices. For example, if a trial has no in-person visits, explain how safety is managed remotely. Ethics committees will scrutinize that, but E6(R3) provides them guidance to do so.
- Annex 2 (Draft) – Further Guidance: Although not part of the final E6(R3) yet, a draft Annex 2 is specifically addressing “non-traditional” trials including those with decentralized, adaptive, or real-world elements. Regulators have signaled through discussions and draft texts that considerations like ensuring data privacy for remote data, training local healthcare providers who participate, providing clear instructions to participants for home procedures, and planning for emergency care in remote settings are vital. While we await the final Annex 2, sponsors should already be mindful of these aspects.
In short, ICH E6(R3) gives permission with conditions: you can decentralize activities, but you must maintain GCP standards through thoughtful planning, documentation, and oversight.
Planning a Decentralized Trial: Regulatory Expectations
When designing a trial with decentralized features, consider the following factors from a regulatory compliance perspective:
- Informed Consent Process: How will consent be obtained? As discussed in Blog #3, electronic and remote consent are acceptable in E6(R3). If you plan to use eConsent, ensure it’s user-friendly and that participants have a way to ask questions (maybe schedule a video chat with the investigator or study nurse). Document how identity verification will be done remotely (e.g., through a secure login or a teleconference ID check). Regulators expect that the remote consent process will mirror the ethical rigor of in-person consent. Plan to provide participants a copy of their consent via email or post, and store the signed consent securely.
- IP Distribution and Accountability: Investigational product (IP, e.g., study drug) handling is a big focus. If drugs are shipped directly to participants, the sponsor must ensure this is done safely and in compliance with regulations (many countries require the trial pharmacy or a certified distributor to oversee this). Critical questions include: How is temperature controlled during shipment? How do we confirm the patient received it? Are they storing it properly at home? One common solution is to use specialty couriers with tracking and to include temperature-monitoring devices in shipments for cold chain products. Participants can be given a simple log or app to record when they receive and take each dose. E6(R3) allows that the investigator doesn’t personally hand the drug to the patient as traditionally, but it doesn’t remove the investigator’s responsibility to know what the patient received and that the drug is authentic and within expiry. So, documentation like shipping records, drug accountability logs (with patients possibly confirming receipt and usage) become essential. Additionally, instructions to participants should be very clear, and ideally, a study nurse or pharmacist calls the participant after receipt to review storage and dosing instructions. All these steps should be described in the protocol or a Pharmacy Manual, and compliance tracked.
- Remote Clinical Assessments: Determine which trial assessments can be done remotely vs. which require in-person visits. Many questionnaires, interviews, even some visual examinations (like a rash via video) can be remote. However, certain procedures (imaging scans, blood draws) might require local facility visits. For each assessment, decide who will do it and where. If local labs or doctors are involved (for instance, a local lab does blood tests, or a participant’s primary care doctor conducts a physical exam for trial purposes), those individuals become essentially part of the trial process. E6(R3) would expect that they are either listed as sub-investigators or their services are contracted with clear responsibilities. For example, if a local lab is used, the lab should be listed and the type of test they’ll perform should be validated (are their methods equivalent to the central lab or reference ranges provided?). If a local physician will do an exam, they should be provided the protocol specifics and possibly sign an agreement or letter of understanding. Often, sponsors provide a “Healthcare Provider Packet” for any external physicians, explaining the trial and their role, along with a form to document findings that goes back to the main site. This keeps things GCP-compliant – just because someone is external doesn’t mean documentation can be lax.
- Home Visits and Local Services: If employing home health nurses or mobile clinical services, ensure training and oversight. The nurses should be trained on GCP (at least basic principles), trial procedures, and reporting lines. They need to know, for instance, what to do if a patient has an adverse event during a home visit (call 911? notify the PI immediately after stabilizing the patient, etc.). Contracts or agreements with these service providers should outline their tasks and the requirement to follow the protocol and report data appropriately. E6(R3) highlights that even when tasks are delegated, the investigator retains responsibility – so the investigator should review any data or reports that home health personnel generate, just as they would data collected in-clinic. One practical tip is having the home nurse fill a visit checklist or report that is then sent to the investigator for review/sign-off. Also, the nurse should be on delegation log if they are considered under the investigator’s direct oversight, or there should be a vendor agreement if they’re not reporting to the investigator.
- Telemedicine and Communication: For telemedicine visits, regulators will want to ensure privacy and data protection. Use secure, encrypted platforms when discussing health information, not open social media or unsecure lines. Document that the tele-visit occurred (many sites include a note, e.g., “Telehealth visit conducted via Zoom on X date, per protocol visit 3. Exam limited due to video format but patient reports… etc.”). If vital signs or other data are self-reported by the patient during a tele-visit, have a method to record their origin (patient-measured BP at home with their device, for example). Perhaps provide patients with calibrated devices (some studies ship participants digital blood pressure cuffs or thermometers). E6(R3) compliance isn’t about forbidding self-report – it’s about ensuring accuracy and documentation. So if a patient is collecting some data, train them how and provide means to record it reliably.
- Safety Monitoring and Reporting: With participants potentially far from the site, have a robust plan for safety monitoring. This may involve more frequent check-ins (phone or text) from study staff to ask about adverse events or remind participants to report any urgent issues. Ensure participants know whom to contact 24/7 in case of concerning symptoms – typically an on-call study physician or a call center. E6(R3) requires same vigilance for safety as any trial: adverse events must be collected and serious ones reported. The challenge in DCTs is making sure you don’t miss events because patients aren’t physically coming in as often. So proactive communication is key. Many decentralized trials use automated texting services, eDiaries with symptom prompts, or regular phone calls to stay in touch. Document these attempts and interactions. Regulators will appreciate seeing that the study did not “set and forget” patients out at home, but actively engaged them throughout to monitor safety.
Practical Implementation Tips for Decentralized Elements
Successfully running a decentralized or hybrid trial requires blending technology and human touch:
- Invest in Participant Training and Support: Participants in decentralized trials take on tasks that site staff would normally handle – like measuring their vitals, keeping their own drug accountability, or using apps to record data. Providing initial training (maybe a home visit or video tutorial when they start) will greatly improve data quality and protocol compliance. Also, maintain tech support for any digital tools. If a patient’s app isn’t working, they need quick assistance or they might drop out or data will be lost. Consider a helpdesk line for technical issues, and have a plan to provide replacement devices if one fails.
- Ensure Data Connectivity and Backup Plans: If a lot of data collection relies on internet connectivity (uploading data from a wearable or filling surveys online), plan for what if connectivity is poor. Perhaps devices can store data offline temporarily and upload later, or the patient can be given paper logs as backup if all else fails. The trial protocol or manual should specify contingency measures: e.g., “If electronic PRO device malfunctions, the patient will be overnight mailed a paper diary to use until resolved.” This way data isn’t completely lost. Keep in mind that regulators will want to know the completeness of data – a decentralized trial shouldn’t inherently have more missing data if managed well. Logging technical outages and their resolution is part of data governance (for audit trail of why data might be missing in a given window).
- Pilot Test Decentralized Processes: Before launching full-scale, do a dry run of key decentralized processes. You might simulate a patient receiving a shipment, going through eConsent, using the eDiary, and have staff follow the flows of data. This internal pilot (or a formal pilot study) can identify kinks – maybe the shipping packaging was confusing, or the consent platform had browser compatibility issues, etc. Fix those early. Regulators appreciate when sponsors pilot new techniques because it shows due diligence in ensuring they work as intended.
- Regulatory Engagement: If your trial is doing something quite novel (like fully remote participation in multiple countries), consider engaging with regulators or ethics committees early. In some cases, you might seek a meeting with an agency to confirm there are no objections to your approach (for example, clarifying if local regulations allow remote consent in all regions you operate). Ethics committees will definitely review these aspects, so in the submission, explicitly describe your decentralized elements in the protocol or a specific document. Many sponsors include a “Decentralized Trial Addendum” to the protocol, detailing all such processes (e.g., remote consent process, home health procedures, etc.) to make review easier. Full transparency helps avoid delays or questions during review – the IRB shouldn’t be guessing how you’ll manage home lab tests; it should be clearly laid out.
- Maintain Participant Engagement: One risk of DCTs is participants feeling less connected to the study since they don’t see study staff as often. Combat this by fostering engagement – regular phone/video visits, newsletters to participants about study progress (if appropriate), or a patient concierge service to help with appointment scheduling for any local tests. Engaged participants are more likely to complete the trial and follow procedures carefully, which directly feeds data quality and trial success. This also touches on an ethical aspect: decentralized doesn’t mean impersonal. E6(R3) principles of respecting participants and keeping them informed still apply. So, for instance, after study end, consider sending a thank-you letter and a lay summary of results to participants (as recommended by GCP). This retains goodwill and demonstrates that despite physical distance, the trial still prioritized the participant’s experience.
Ensuring Data Quality and GCP in DCTs
Regulators will judge a decentralized trial by its outcomes: did it safeguard patients and produce reliable data? To ensure the answer is yes:
- Implement a strong central monitoring plan (tying into RBM, as in Blog #2). With activities spread out, central monitoring becomes your glue to see the full picture. Use data analytics to combine inputs from various sources (eDiary data, sensor data, site-reported data) and look for inconsistencies or gaps. For example, if a patient reports taking medication daily on the app but pill counts from returned bottles show many pills left, that discrepancy must be flagged and investigated.
- Protect Data Privacy: DCTs often generate personal data in non-traditional ways (video recordings, GPS data from devices, etc.). Ensure compliance with privacy laws – obtain explicit consent for what data will be collected (the consent form should mention any extra data like tracking or recording if applicable), and secure that data. Use encryption for any data in transit (like from a wearable to a server). If using third-party services or cloud platforms, have data processing agreements in place. Regulators in the EU especially will check that GDPR considerations are handled. Incorporating privacy-by-design in your trial tech is part of data governance.
- Audit Trails for Remote Processes: Try to capture logs for remote activities. Many decentralized trial platforms produce audit trails (e.g., log of when questionnaires were completed, when a telehealth call occurred). Keep those logs – they can be useful if you ever need to confirm an event. For instance, if a patient disputes that they were ever consented properly because it was remote, your audit trail showing their login and e-signature, plus a recording or transcript of the consent call (if available), could resolve the issue. While we hope such disputes are rare, having evidence is crucial.
- Monitor Protocol Deviations Differently: In a DCT, what constitutes a protocol deviation might differ. For example, if a patient can’t travel for an in-person assessment and you arrange a local doctor visit, technically you deviated from the original plan (change of assessment location). It’s a good practice to prospectively identify which deviations are expected or allowed due to decentralized approach and get IRB approval for those contingencies. But truly unexpected deviations (like missed remote visits, or a home nurse unable to collect a sample) should still be logged and categorized. Use that log to continuously improve: if you see a trend that many patients miss a certain assessment because it’s too complicated to do at home, you might simplify or remove that assessment in a protocol amendment. E6(R3) encourages using a risk-based approach to even protocol compliance – address systematic issues that create deviations.
Conclusion: Decentralization with Rigor
Decentralized trials offer tremendous opportunity to reach more diverse participants, improve convenience, and potentially speed up trials, but they must be approached with the same or greater rigor than traditional trials. ICH E6(R3) effectively says: “You can take the trial to the patient, but you cannot compromise on ethics or quality while doing so.”
For stakeholders, this means meticulous planning of every remote component, clear communication channels, and leveraging technology without losing the human oversight element. Many sponsors are finding that a hybrid model works best – some in-person touchpoints combined with remote follow-ups – to balance data quality and patient convenience.
From a regulatory perspective, the good news is that agencies are supportive of decentralized trials when done correctly. The FDA, EMA, and others have issued guidance reflecting flexibility, much of which E6(R3) captures. Regulators recognize that DCTs can address long-standing challenges like patient access, but they will scrutinize how you maintain GCP standards in the new model. By preemptively addressing those concerns – security, training, documentation, oversight – as described above, you can demonstrate that your decentralized trial is just as robust as a traditional one.
In practice, many decentralized trials have shown high enrollment and retention rates, and even improved data timeliness (e.g., direct data capture from patients in real-time). When participants are comfortable and well-supported, they are more likely to adhere to the study, which directly benefits data completeness and reliability. The ultimate goal aligns with GCP: trials that are ethical, efficient, and yield credible results. Decentralized methods, guided by E6(R3)’s flexible but firm requirements, are proving to be a viable path to that goal. Sponsors and investigators who adapt to this approach will likely be at the forefront of clinical research innovation in the years to come, delivering trials that fit into patients’ lives while meeting the highest standards of quality.
References
- ICH Guideline for Good Clinical Practice E6(R3), Final Step-4 Guideline, Jan 6, 2025. [1]
- “The revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice,” Arun Bhatt, Perspectives in Clinical Research, 2023. [3]
- TransCelerate/ACRO’s E6(R3) Asset Library: tools on trial design, risk management, data governance. [5]
For those interested in gaining our Transcelerate Biopharma-certified courses, please enroll in our ICH GCP E6 R3 courses at https://www.whitehalltraining.com/
#GCPE6R3 #ClinicalTrials #ICHGuidelines #ClinicalResearch #ICH #E6R3 #GCP #WhitehallTraining #CRO #GoodCllinicalPractice #ClinicalTrials
Guidance To Explore
For those wanting to dive deeper into the details:
- ICH E6 (R3) Final Guideline (Step 4, January 6, 2025) – The official reference text.
- FDA Overview of ICH E6 (R3) – A clear outline of the changes and their implications.
- EMA Step 5 Guideline – European regulatory perspective on implementation.
- TransCelerate ICH E6 Asset Library – Practical tools and frameworks to support adoption (TransCelerate).
Leave a Reply